期刊
PARKINSONISM & RELATED DISORDERS
卷 20, 期 12, 页码 1388-1393出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2014.10.005
关键词
Parkinson's disease; Treatment; Randomized trial; Rotigotine; Ropinirole
资金
- Otsuka Pharmaceutical Co., Ltd.
- FP Pharmaceutical Corporation
- Novartis Pharma K.K.
- GlaxoSmithKline K.K.
- Nippon Boehringer Ingelheim Co., Ltd.
- Dainippon Sumitomo Pharma Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
Objective: To confirm the superiority of transdermal rotigotine up to 16 mg/24 h over placebo, and non-inferiority to ropinirole, in Japanese Parkinson's disease (PD) patients on concomitant levodopa therapy. Methods: This trial was a randomized, double-blind, double-dummy, three-arm parallel group placebo- and ropinirole-controlled trial. Four-hundred and twenty PD patients whose motor symptoms were not well controlled by levodopa treatment were randomized 2:2:1 to receive rotigotine, ropinirole (up to 15 mg/day) or placebo during a 16-week treatment period followed by a 4-week taper period. The primary variable was change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (ON state) sum score from baseline to the end of the treatment period. Results: The difference in the change in the UPDRS Part III (ON state) sum score from baseline to the end of treatment between rotigotine and placebo groups was -6.4 +/- 1.2 (95% CI: -8.7 to -4.1; p < 0.001), indicating superiority of rotigotine over placebo. The difference between rotigotine and ropinirole groups was -1.4 +/- 1.0 (95% Cl: -3.2 to 0.5), below the non-inferiority margin, indicating the non-inferiority of rotigotine to ropinirole. Application site reaction was seen in 57.7% of the patients in the rotigotine group and in 18.6% in the ropinirole group (P < 0.001). No other safety issue was noted. Conclusions: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed similar efficacy to ropinirole except that the application site reaction was much higher in the rotigotine group. (C) 2014 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据